Information Provided By: 
Fly News Breaks for March 31, 2016
LIFE
Mar 31, 2016 | 05:47 EDT
William Blair analyst Y. Katherine Xu downgraded aTyr Pharma to Market Perform and lowered her price target for the shares to $8 from $42 citing the "mixed" Phase Ib/II trial data of Resolaris in adult patients with late-onset facioscapulohumeral muscular dystrophy. ATyr will likely have to conduct a larger, placebo-controlled Phase II trial to explore objective endpoints that could ultimately be used in a pivotal study for approval, Xu tells investors in a research note. This could push approval out to 2021, the analyst contends.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
